



Title	The new cardiovascular continuum
Author(s)	Cheung, BMJ
Citation	Hong Kong Medical Journal, 2006, v. 12 n. 2, p. 161-163
Issued Date	2006
URL	http://hdl.handle.net/10722/45020
Rights	Creative Commons: Attribution 3.0 Hong Kong License

The new cardiovascular continuum

The cardiovascular continuum

The cardiovascular continuum was first proposed by Dzau and Braunwald¹ in 1991 as a new paradigm for cardiovascular diseases (Fig). It arose from the realisation that cardiovascular events such as heart failure and myocardial infarction are really late complications in a chain of events that starts with a number of cardiovascular risk factors and continues as a progressive pathogenic process lasting for decades. Atherosclerosis, myocardial necrosis, and heart failure cannot be reversed easily, if at all, so addressing the early components of the continuum—such as hypertension, diabetes, hyperlipidaemia, and smoking—offers a chance of arresting the progression of cardiovascular disease at an early stage. These cardiovascular risk factors are rarely immediately life-threatening, but because they are asymptomatic, much effort has been devoted to screen for them and to modify them by lifestyle changes and drug treatment.²

Antihypertensive drugs and statins demonstrate the clinical utility of the cardiovascular continuum concept, namely, that the correction of cardiovascular risk factors prevents escalation of cardiovascular disease and downstream complications including myocardial infarction, stroke, and ultimately, death.^{2,3} Angiotensin-converting enzyme inhibitors, for example, address different parts of the continuum, including hypertension, diabetes, left ventricular hypertrophy, remodelling, and heart failure.¹ Research into cardiovascular risk factors suggests that 80% of cardiovascular events can be prevented, using either existing drugs or the “polypill”.⁴ Can we do better by preventing cardiovascular disease itself?

Obesity and the metabolic syndrome

Hypertension, diabetes, and hyperlipidaemia are all related to obesity as part of the metabolic syndrome, which was first identified by Reaven⁵ nearly two decades ago. In fact, type 2 diabetes, hyperlipidaemia, and hypertension all respond to diet and weight control.^{2,6} Conventionally, the body mass index (BMI) is used to quantify obesity, and in Asia, a BMI of 23 is already associated with a much increased cardiovascular risk. However, waist circumference is more closely associated with cardiovascular risk than BMI.⁷ Abdominal obesity results in insulin resistance and the metabolic syndrome through multiple and complex mechanisms, such as the active role adipose tissues play in energy homeostasis and the secretion of hormones, including leptin, adiponectin, resistin, and acylation-stimulating protein, that regulate appetite and insulin sensitivity.⁸ Thus, abdominal or central obesity (which is more common in men than women) is clearly a target for intervention.

Obesity and inflammation

In adipose tissues, fat-laden adipocytes attract macrophages and initiate a vicious cycle of inflammation.⁹ Plasma C-reactive protein (CRP), an inflammatory marker, increases with obesity, even in children¹⁰; losing weight reduces it. Elevated CRP levels are predictive of future development of diabetes and cardiovascular events.¹¹

Adipocytes also secrete tumour necrosis factor alpha and plasminogen activator inhibitor-1.⁸ Inflammation in adipose tissues is, therefore, an early event in the cardiovascular continuum, preceding the development of diabetes, endothelial dysfunction, and atherosclerotic disease. An increase in pro-inflammatory cytokines and a decrease in adiponectin may lead to endothelial dysfunction and facilitate the development of hypertension and atherosclerosis.

Diet and obesity

Obesity is caused by calorie intake in excess of energy requirements. In modern, urban society, automation and the ready availability and commercial promotion of foods with high energy content all contribute to weight gain. Exercise reduces body weight and reverses endothelial dysfunction,¹² but the amount of exercise recommended in the latest WHO directive¹³ (at least 30 minutes each day) is often not feasible without profound changes in lifestyle, such as fewer social engagements, and less television viewing and internet use. Publications in leading journals suggest that the current recommendation of a low-fat high-carbohydrate diet may be wrong: a low carbohydrate diet is more effective than a low-fat diet in inducing weight loss.¹⁴ Dr Atkins was right: one can eat steaks and lose weight effectively. Surprisingly, a low carbohydrate diet will significantly raise high density lipoprotein-cholesterol but not low density lipoprotein-cholesterol, and will reduce plasma triglycerides and CRP.¹⁵

Not all carbohydrates are equally bad. The concept of the glycaemic index is useful and is directly relevant to diabetes and the metabolic syndrome. Foods with high glycaemic indices are undesirable because a high blood glucose peak stimulates insulin secretion, causing hunger a few hours later.¹⁶ Foods with low glycaemic indices release glucose more gradually. In a study in laboratory animals comparing diets of low and high glycaemic indices with the same total calories, rats and mice weighed the same in both groups, but the animals fed the high glycaemic index diet had twice as much body fat and a lower lean body mass.¹⁷

Polished rice, the staple food in much of Asia, is low in fibre with a high glycaemic index ranging from 50 to 94, depending on the variety of rice and how it is cooked. Congee, popularly believed to be a healthy food item, can




Fig. The cardiovascular continuum

The two boxes in dotted lines at the bottom are hypothetical (adapted from Dzau and Branwald¹)

cause a particularly high peak in plasma glucose. Rice-based meals have a place in rural societies where people walk a lot and perform manual labour. To take a traditional Asian example, Sumo wrestlers have a lot of subcutaneous fat, but have little visceral fat because of heavy exercise. However, the appropriateness of such a diet for an urbanised society is now questionable. The Chinese diet, with low fat content and an abundance of green vegetables and rice, is comparable with the Mediterranean diet in healthiness. Paradoxically, Chinese populations have a very high incidence of impaired glucose tolerance. In the Hong Kong Cardiovascular Risk Factor Prevalence Survey-2 (CRISPS2) cohort,¹⁸ one third of those who were over the age of 65 years had diabetes. A nutritional survey of the same cohort showed that the intake of rice and pasta

was higher in diabetics of normal body weight.¹⁹ Thus obesity and insulin resistance in much of Asia are not due to excess fat in the diet, but to carbohydrate intake in excess of energy expenditure requirements (Fig).

A new paradigm

Hypertension, diabetes, dyslipidaemia, and obesity need not be treated in different clinics using different sets of drugs. Obesity is at the centre of the metabolic syndrome and should be treated as seriously as hypertension and diabetes. Treatment of obesity not only reduces body weight, but also waist circumference, blood pressure, plasma glucose, and lipids. In theory, a change in diet should work; lifestyle changes have been shown to prevent

hypertension and diabetes.^{6,20} A “polymeal” has been proposed as an alternative to the “polypill” to prevent cardiovascular disease through nutrition rather than drugs.²¹ In practice, however, therapeutic lifestyle changes are plagued by poor compliance and high drop-out rates.

There are only five drugs currently approved by US Food and Drug Administration for the treatment of obesity, orlistat and sibutramine being the most widely used. If people cannot change their dietary habits, then drugs are needed to combat excess carbohydrates in the same way statins are used in hypercholesterolaemia. This is an area that urgently requires intensive research, as the epidemic of obesity is happening here and now. We can start by discarding the food pyramid, which, rather like those other pyramids in Egypt, is now of mainly historical interest. The US Department of Agriculture has now replaced the food pyramid with My Pyramid (<http://www.mypyramid.gov>), which is a step in the right direction to address the problem of obesity and cardiovascular health.

Acknowledgements

The Hong Kong Cardiovascular Risk Factor Prevalence Survey-2 (CRISPS2) is supported by the Research Grants Council and the Sun Chieh Yeh Heart Foundation.

BMJ Cheung, PhD, FHKAM (Medicine)
(e-mail: mycheung@hkucc.hku.hk)
Department of Medicine
University of Hong Kong
Queen Mary Hospital
Hong Kong

References

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. *Am Heart J* 1991;121:1244-63.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
3. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol* 2004;57:640-51.
4. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. *BMJ* 2003;326:1419.
5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988;37:1595-607.
6. Cheung BM, Lam TC. Hypertension and diet. In: Caballero B, Trugo LC, Finglas PM, editors. *Encyclopaedia of food sciences and nutrition*. London: Academic Press; 2003:3194-9.
7. Ko GT, Chan JC, Cockram CS, Woo J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. *Int J Obes Relat Metab Disord* 1999; 23:1136-42.
8. Rajala MW, Scherer PE. Minireview: The adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* 2003;144:3765-73.
9. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. *J Clin Invest* 2003;112:1785-8.
10. Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. *J Pediatr* 2001;138:486-92.
11. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 1999;19:972-8.
12. Woo KS, Chook P, Yu CW, et al. Effects of diet and exercise on obesity-related vascular dysfunction in children. *Circulation* 2004; 109:1981-6.
13. WHO resolution WHA51.17. Global strategy on diet, physical activity and health. 57th World Health Assembly; 22 May 2004.
14. Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med* 2003; 348:2074-81.
15. Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. *Am J Med* 2004;117:398-405.
16. Brand-Miller JC, Holt SH, Pawlak DB, McMillan J. Glycemic index and obesity. *Am J Clin Nutr* 2002;76:281S-285S.
17. Pawlak DB, Kushner JA, Ludwig DS. Effects of dietary glycaemic index on adiposity, glucose homeostasis, and plasma lipids in animals. *Lancet* 2004;364:778-85.
18. Cheung BM, Lam TH, Lam KS, et al. The Hong Kong Cardiovascular Risk Factor Prevalence Survey cohort —results at 7 years. *J Hypertens* 2004;22(Suppl 2):268S-269S.
19. Woo J, Ho SC, Sham A, et al. Diet and glucose tolerance in a Chinese population. *Eur J Clin Nutr* 2003;57:523-30.
20. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-50.
21. Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. *BMJ* 2004;329:1447-50.